☰

Irem Ozkan-Dagliyan - Publications

Affiliations: 
Department of Pharmacology University of North Carolina, Chapel Hill, Chapel Hill, NC 
Area:
Cancer biology
Tree Info Similar researchers PubMed Report error

8 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2022 Goodwin CM, Waters AM, Klomp JE, Javaid S, Bryant KL, Stalnecker CA, Drizyte-Miller K, Papke B, Yang R, Amparo AM, Ozkan-Dagliyan I, Baldelli E, Calvert V, Pierobon M, Sorrentino JA, et al. Combination Therapies with CDK4/6 Inhibitors to Treat KRAS-mutant Pancreatic Cancer. Cancer Research. PMID 36346366 DOI: 10.1158/0008-5472.CAN-22-0391  0.538
2021 Diehl JN, Hibshman PS, Ozkan-Dagliyan I, Goodwin CM, Howard SV, Cox AD, Der CJ. Targeting the ERK mitogen-activated protein kinase cascade for the treatment of KRAS-mutant pancreatic cancer. Advances in Cancer Research. 153: 101-130. PMID 35101228 DOI: 10.1016/bs.acr.2021.07.008  0.487
2020 Ozkan-Dagliyan I, Diehl JN, George SD, Schaefer A, Papke B, Klotz-Noack K, Waters AM, Goodwin CM, Gautam P, Pierobon M, Peng S, Gilbert TSK, Lin KH, Dagliyan O, Wennerberg K, et al. Low-Dose Vertical Inhibition of the RAF-MEK-ERK Cascade Causes Apoptotic Death of KRAS Mutant Cancers. Cell Reports. 31: 107764. PMID 32553168 DOI: 10.1016/J.Celrep.2020.107764  0.521
2018 Vaseva AV, Blake DR, Gilbert TSK, Ng S, Hostetter G, Azam SH, Ozkan-Dagliyan I, Gautam P, Bryant KL, Pearce KH, Herring LE, Han H, Graves LM, Witkiewicz AK, Knudsen ES, et al. KRAS Suppression-Induced Degradation of MYC Is Antagonized by a MEK5-ERK5 Compensatory Mechanism. Cancer Cell. 34: 807-822.e7. PMID 30423298 DOI: 10.1016/J.Ccell.2018.10.001  0.543
2018 Dagliyan O, Krokhotin A, Ozkan-Dagliyan I, Deiters A, Der CJ, Hahn KM, Dokholyan NV. Computational design of chemogenetic and optogenetic split proteins. Nature Communications. 9: 4042. PMID 30279442 DOI: 10.1038/S41467-018-06531-4  0.466
2017 Waters AM, Ozkan-Dagliyan I, Vaseva AV, Fer N, Strathern LA, Hobbs GA, Tessier-Cloutier B, Gillette WK, Bagni R, Whiteley GR, Hartley JL, McCormick F, Cox AD, Houghton PJ, Huntsman DG, et al. Evaluation of the selectivity and sensitivity of isoform- and mutation-specific RAS antibodies. Science Signaling. 10. PMID 28951536 DOI: 10.1126/Scisignal.Aao3332  0.44
2014 Ye R, Selby CP, Chiou YY, Ozkan-Dagliyan I, Gaddameedhi S, Sancar A. Dual modes of CLOCK:BMAL1 inhibition mediated by Cryptochrome and Period proteins in the mammalian circadian clock. Genes & Development. 28: 1989-98. PMID 25228643 DOI: 10.1101/Gad.249417.114  0.467
2013 Ozkan-Dagliyan I, Chiou YY, Ye R, Hassan BH, Ozturk N, Sancar A. Formation of Arabidopsis Cryptochrome 2 photobodies in mammalian nuclei: application as an optogenetic DNA damage checkpoint switch. The Journal of Biological Chemistry. 288: 23244-51. PMID 23833191 DOI: 10.1074/Jbc.M113.493361  0.458
Show low-probability matches.